Want to see AU:ATH full AI Analyst Report?
ATH Stock Chart & Stats
AU$0.01
>-AU$0.01(-10.00%)
At close: 4:00 PM EST
AU$0.01
>-AU$0.01(-10.00%)
Day’s Range― - ―
52-Week RangeAU$0.35 - AU$0.85
Previous CloseN/A
Volume25.42M
Average Volume (3M)16.33M
Market Cap
AU$140.35M
Enterprise ValueAU$78.21M
Total Cash (Recent Filing)AU$49.20M
Total Debt (Recent Filing)AU$163.91K
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding217,589,160
10 Day Avg. Volume24,202,939
30 Day Avg. Volume16,327,471
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.95Price Target Upside9400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$5.95M
Bulls Say, Bears Say
Bulls Say
Proprietary R&D PlatformOwning a proprietary small-molecule iron-modulating platform is a durable scientific and IP asset. It enables multiple program extensions, strengthens bargaining power for partnerships or licensing, and supports long-term pipeline optionality across neurodegenerative indications.
Focused On High-Unmet-Need IndicationA focused strategy on disease‑modifying therapies for neurodegeneration (MSA) aligns with structural, long-duration unmet medical need. Progress in this space creates lasting commercial and partnership value if clinical milestones are met, attracting sustained interest.
Very Low LeverageMinimal financial leverage reduces solvency and interest burden risk, providing balance-sheet flexibility. For a clinical-stage biotech this lowers near-term default risk and supports strategic options (equity, partnerships, non-dilutive funding) while pursuing trials.
Bears Say
No Recurring RevenueRelying on capital raises rather than product cash flow is a durable business-model risk. It creates ongoing financing and execution risk, increases dilution over time, and ties program continuity to external market access rather than internal cash generation.
Persistent Negative Cash FlowSustained negative operating and free cash flows indicate ongoing cash burn and weak conversion of activities into cash. Over a 2-6 month horizon this elevates the need for fresh funding, increasing dilution risk and pressure on execution of clinical programs.
Lack Of Profitability / Negative ROENegative margins and a reported negative ROE reflect inability to generate returns from operations or shareholder equity. Until clinical success or commercialization occurs, the company lacks sustainable profit drivers, limiting durable value creation for shareholders.
Alterity Therapeutics News
ATH FAQ
What was Alterity Therapeutics’s price range in the past 12 months?
Alterity Therapeutics lowest share price was AU$0.35 and its highest was AU$0.85 in the past 12 months.
What is Alterity Therapeutics’s market cap?
Alterity Therapeutics’s market cap is AU$140.35M.
When is Alterity Therapeutics’s upcoming earnings report date?
Alterity Therapeutics’s upcoming earnings report date is Mar 04, 2027 which is in 236 days.
How were Alterity Therapeutics’s earnings last quarter?
Alterity Therapeutics released its earnings results on Feb 25, 2026. The company reported -AU$0.045 earnings per share for the quarter, missing the consensus estimate of -AU$0.029 by -AU$0.016.
Is Alterity Therapeutics overvalued?
According to Wall Street analysts Alterity Therapeutics’s price is currently Undervalued.
Does Alterity Therapeutics pay dividends?
Alterity Therapeutics does not currently pay dividends.
What is Alterity Therapeutics’s EPS estimate?
Alterity Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics have?
Alterity Therapeutics has 217,589,160 shares outstanding.
What happened to Alterity Therapeutics’s price movement after its last earnings report?
Alterity Therapeutics reported an EPS of -AU$0.045 in its last earnings report, missing expectations of -AU$0.029. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Alterity Therapeutics?
Currently, no hedge funds are holding shares in AU:ATH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.95 (9400.00% Upside)
AU$0.95 (9400.00% Upside)
Blogger Sentiment
Bullish
AU:ATH Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
ATH Stock 12 Month Forecast
Average Price Target
AU$0.95
▲(9400.00% Upside)
Technical Analysis
Actinogen Medical
―
Cynata Therapeutics Limited
―
Tryptamine Therapeutics
―
Living Cell Technologies
―
Neuren Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---